Table 1.
Comparison between the studies on demographics and cognitive performance
| ADNI (n = 330) Mean (SD) |
AIBL (n = 161) Mean (SD) |
HABS (n=268) Mean (SD) |
F, χ2 | Effect size (ηp2 or Cramer’s V) |
p | |
|---|---|---|---|---|---|---|
| Follow-up (yrs) | 3.29 (1.2) | 4.99 (1.3) | 4.56 (1.3) | 129.1 | 0.26 | <0.001 |
| Age | 74.6 (6.5) | 71.6 (6.8)* | 73.4 (6.0) | 11.3 | 0.03 | <.001 |
| Females (n/%) | 173 (52%) | 86 (53%) | 159 (59%) | 3.1 | 0.06 | 0.21 |
| Years of | 16.4 (2.7) | 13.7 (2.2)* | 15.8 (3.0) | 53.8 | 0.12 | <0.001 |
| Education | ||||||
| APOEε4+ (n/%) | 88 (27%) | 49 (32%) | 67 (27%) | 1.13 | 0.04 | 0.56 |
| Aβ SUVr (FBPequiv) | 1.04 (0.2) | 1.05 (0.2) | 1.04 (0.2) | 0.23 | 0.0006 | 0.79 |
| Aβ + status (n/%) | 96 (29%) | 46 (29%) | 76 (28%) | 0.01 | 0.004 | 0.99 |
| MMSEbaseline | 29 (1.2) | 29 (1.2) | 29 (1.1) | 0.37 | 0.001 | 0.69 |
| PACCbaseline | 0.03 (0.6) | 0.07 (0.6) | 0.02 (0.7) | 0.34 | 0.001 | 0.71 |
| PACCslope | −0.05 (0.2) | −0.03 (0.2) | −0.03 (0.2) | 1.01 | 0.003 | 0.36 |
Note: ADNI = Alzheimer’s Disease Neuroimaging Initiative; Australian Imaging, Biomarker and Lifestyle (AIBL) study; HABS = Harvard Aging Brain Study (HABS); SD = standard deviation; FBPequiv = Florebetapir equivalent score; APOE = apolipoprotein